Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer

Liu, Yutao; Han, Xiaohong; Xing, Puyuan; Hu, Xingsheng; Hao, Xuezhi; Wang, Yan; Li, Junling; Zhang, Zhishang; Yang, Zhihao; Shi, Yue

doi:10.21037/jtd.2019.05.22

Cited by 35 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Predictive and identify biomarkers are urgently needed for patients with NSCLC. Previous studies indicated that some circRNAs are associated with the development of NSCLC, which participated in multiple biological processes, such as cell proliferation, apoptosis and metastasis (6,22,23). Zhang et al found that hsa_circ_0014130 was aberrantly expressed in NSCLC tissues and might be a new circular RNA biomarker in NSCLC (10).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non–Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2

Geng

Bao

Zhang

et al. 2020

Molecular Cancer Research

View full text Add to dashboard Cite

Previous studies indicated that circular RNAs (circRNAs) played vital roles in the development of non-small-cell lung cancer (NSCLC). Although hsa_circ_0014130 might be a potential NSCLC biomarker, its function in NSCLC remains unknown. Thus, this study aimed to investigate the role of hsa_circ_0014130 in the progression of NSCLC. The levels of hsa_circ_0014130 in NSCLC tissues and adjacent normal tissues were determined by RT-qPCR. In addition, the expressions of Bcl-2, cleaved caspase 3 in A549 cells were detected with western blot. Meanwhile, the dual luciferase reporter system assay was used to determine the interaction of hsa_circ_0014130 and miR-136-5p, or Bcl-2 and miR-136-5p in NSCLC respectively. The level of hsa_circ_0014130 was significantly upregulated in NSCLC tissues. Downregulation of hsa_circ_0014130 markedly inhibited the proliferation and invasion of A549 cells via inducing apoptosis. In addition, downregulation of hsa_circ_0014130 inhibited the tumorigenesis of subcutaneous A549 xenograft in mice in vivo. Meanwhile, mechanistic analysis indicated that downregulation of hsa_circ_0014130 decreased the expression of miR-136-5p targeted gene Bcl-2 via acting as a competitive 'sponge' of miR-136-5p. In this study, we found that hsa_circ_0014130 was upregulated in NSCLC tissues. In addition, hsa_circ_0014130 functions as a tumor promoter in NSCLC to promote tumor growth through up-regulating Bcl-2 partially via 'sponging' miR-136-5p. Implications statementIn conclusion, hsa_circ_0014130 might function as a prognostic factor for patients with NSCLC and might be a therapeutic target for the treatment of NSCLC in future.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is important to explore novel therapeutic targets for NSCLC. Circular RNAs (circRNAs) are a class of non-coding RNA molecules, which was formed by exon back-splicing (6). CircRNAs extensively exist in mammalian cells, which have a closed loop structure without 5' cap and 3' tail (7).…”

Section: Introductionmentioning

confidence: 99%

Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non–Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2

Geng

Bao

Zhang

et al. 2020

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…In addition, the annular structure endows circRNAs with inherent stability, which enables them to accumulate in exosomes and exist stably in peripheral body fluids such as plasma and saliva. All these elucidate the potential of circRNAs as markers for diagnosis and therapy of cancers [193][194][195]. It has been found that circRNAs not only contribute to development and metastasis of malignances, but also are involved in chemoresistance [196][197][198][199].…”

Section: Circrnas and Chemoresistance In Gastric Cancermentioning

confidence: 89%

Noncoding RNAs in gastric cancer: implications for drug resistance

et al. 2020

View full text Add to dashboard Cite

Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer.

show abstract

“…However, acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) remains inevitable [178]. Liu et al [179] reported that circRNAs may act as predictive biomarkers for the efficacy of gefitinib therapy. A total of 1377 differentially expressed circRNAs in the plasma of patients with EGFR-mutant NSCLC were identified by microarray analysis; of these circRNAs, 989 were upregulated and 388 were downregulated.…”

Section: Targeted and Immunotherapeutic Drugsmentioning

confidence: 99%

CircRNAs in anticancer drug resistance: recent advances and future potential

Wang

Jiang

et al. 2020

Mol Cancer

View full text Add to dashboard Cite

CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Numerous studies have indicated that circRNAs serve a crucial purpose in cancer biology. CircRNAs regulate tumor behavioral phenotypes such as proliferation and migration through various molecular mechanisms, such as miRNA sponging, transcriptional regulation, and protein interaction. Recently, several reports have demonstrated that they are also deeply involved in resistance to anticancer drugs, from traditional chemotherapeutic drugs to targeted and immunotherapeutic drugs. This review is the first to summarize the latest research on circRNAs in anticancer drug resistance based on drug classification and to discuss their potential clinical applications.

show abstract

Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer

Cited by 35 publications

References 15 publications

Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non–Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2

Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non–Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2

Noncoding RNAs in gastric cancer: implications for drug resistance

CircRNAs in anticancer drug resistance: recent advances and future potential

Contact Info

Product

Resources

About